Five-year follow-up of randomized clinical trial for pre-emptive inferior mesenteric artery embolization during endovascular aneurysm repair

医学 栓塞 腰动脉 肠系膜下动脉 腔内修复术 随机对照试验 外科 动脉瘤 试验装置豁免 临床终点 放射科 腹主动脉瘤 临床试验 内科学
作者
Yuriko Takeuchi,Noriyasu Morikage,Makoto Samura,Ryunosuke Sakamoto,Soichi Ike,Takahiro Mizoguchi,Takasuke Harada,Hiroshi Kurazumi,Ryo Suzuki,Kotaro Suehiro,Kimikazu Hamano
出处
期刊:Journal of Vascular Surgery [Elsevier BV]
卷期号:80 (3): 693-701.e3 被引量:21
标识
DOI:10.1016/j.jvs.2024.04.058
摘要

OBJECTIVE: Type II endoleak (T2EL) is the most common type of endoleak after endovascular aneurysm repair (EVAR) and a common indication for reintervention due to late sac enlargement. Although pre-emptive embolization of the inferior mesenteric artery (IMA) has been proposed to prevent this, no studies have prospectively demonstrated its efficacy. This study aimed to prove the validity of IMA embolization during EVAR in selective cases by analyzing the mid-term outcomes of a randomized clinical trial (RCT). METHODS: This single-center, parallel-group, non-blinded RCT included participants at high risk of T2EL, characterized by a patent IMA in conjunction with one or more following risk factors: a patent IMA ≥3 mm in diameter, lumbar arteries ≥2 mm in diameter, or an aortoiliac-type aneurysm. The participants were randomly assigned to two groups in a 1:1 ratio: one undergoing EVAR with IMA embolization and the other without. The primary endpoint was T2EL occurrence. The secondary endpoints included aneurysm sac changes and reintervention. In addition to RCT participants, outcomes of patients with low risk of T2EL were also analyzed. RESULTS: The embolization and non-embolization groups each contained 53 patients. Five-year follow-up after the last patient enrollment revealed that T2ELs occurred in 28.3% and 54.7% of patients in the IMA embolization and non-embolization groups, respectively (P = .006). Both freedom from T2EL-related sac enlargement ≥5 mm and cumulative incidence of sac shrinkage ≥5 mm were significantly higher in the IMA embolization group than in the non-embolization group (95.5% vs 73.6% at 5 years; P = .021; 54.2% vs 33.6% at 5 years; P = .039, respectively). The freedom from T2EL-related sac enlargement ≥10 mm, an alternative indicator for T2EL-related reintervention, showed similar results (100% vs 90.4% at 5 years; P = .019). Outcomes in the low-risk group were preferable than those in the non-embolization group and comparable to those in the IMA embolization group. CONCLUSIONS: A lower threshold for pre-emptive IMA embolization when implementing EVAR would be more appropriate if limited to patients at high risk of T2ELs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苏苏苏发布了新的文献求助10
2秒前
所所的应助被何莉采纳,获得10
2秒前
bnn完成签到 ,获得积分10
2秒前
2秒前
文艺冰露完成签到,获得积分10
3秒前
无极微光的应助被北风北风采纳,获得20
3秒前
3秒前
5秒前
aso完成签到,获得积分10
6秒前
刘哈哈完成签到,获得积分10
6秒前
ZQP发布了新的文献求助10
6秒前
xinjie完成签到,获得积分10
8秒前
冬东东完成签到,获得积分10
8秒前
zhulinling发布了新的文献求助10
9秒前
biubiu完成签到 ,获得积分10
10秒前
摸鱼大王发布了新的文献求助10
10秒前
懒羊羊完成签到,获得积分10
11秒前
hello发布了新的文献求助10
11秒前
共享精神的应助被Mr鹿采纳,获得10
11秒前
NexusExplorer的应助被发文章12138采纳,获得10
11秒前
三心发布了新的文献求助20
12秒前
熙原完成签到,获得积分10
12秒前
13秒前
13秒前
弗洛伊德的梦完成签到,获得积分10
15秒前
我是老大的应助被罗二狗采纳,获得10
17秒前
AN发布了新的文献求助30
17秒前
18秒前
Y元郁Y发布了新的文献求助10
19秒前
19秒前
科研通AI6.3的应助被PhDL1采纳,获得10
19秒前
20秒前
zhulinling完成签到,获得积分10
20秒前
20秒前
21秒前
彭于晏的应助被lzqsg采纳,获得10
22秒前
阔达晓蓝发布了新的文献求助10
22秒前
22秒前
李爱国的应助被IY采纳,获得10
23秒前
Laura发布了新的文献求助10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189431
求助须知:如何正确求助?哪些是违规求助? 9576755
关于积分的说明 21849578
捐赠科研通 7787361
什么是DOI,文献DOI怎么找? 3435577
关于科研通互助平台的介绍 2559772
邀请新用户注册赠送积分活动 2482529